safetyriskБезопасность и риск фармакотерапииSafety and Risk of Pharmacotherapy2312-78212619-1164Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)safetyrisk-19Research ArticleОБЗОРЫ И ОРИГИНАЛЬНЫЕ СТАТЬИREVIEWS AND ORIGINAL ARTICLESМониторинг безопасности зарегистрированных лекарственных средств у беременных: фармакогенетические аспектыMonitoring post-approval drug safety in pregnancy: pharmacogenetic aspectsСоковаЕлена АлександровнаSokova2@rambler.ruФедеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской ФедерацииRussian Federation201520022018033035Copyright © Сокова Е.А., 20182018Сокова Е.А.Сокова Е.А.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.risksafety.ru/jour/article/view/19

В статье рассматриваются новые фармакогенетические подходы в оценке безопасности применения зарегистрированных лекарственных средств при беременности, позволяющие прогнозировать риски фармакотерапии как для беременной женщины, так и для плода при проведении фармаконадзора.

The purpose of this article is to describe and to examine the utility of new pharmacogenetic approaches in monitoring post-approval drug safety in pregnancy. Data on gene expression in pregnancy and metabolic variation may, in specific instances, help to predict adverse drug reactions in the mother-placenta-fetus complex and to identify individuals at a higher risk.

беременностьлекарственное средствобезопасностьфармакогенетикафармаконадзорpregnancydrugssafetypharmacogeneticspharmacovigilanceReferencesAdvances in FDA’s Safety Program for Marketed Drugs. Drug Safety Report April 2012. Center for Drug Evaluation and Research U.S. Food and Drug Administration U.S. Health and Human Services A.Advances in FDA’s Safety Program for Marketed Drugs. Drug Safety Report April 2012. Center for Drug Evaluation and Research U.S. Food and Drug Administration U.S. Health and Human Services A.Atkinson D., Brice-Bennet S., D’souza S.W. Antiepileptic medication during pregnancy: does fetal genotype affect outcome? Pediatric research 2007; 62(2): 120-127.Atkinson D, Brice-Bennet S, D’souza SW. Antiepileptic medication during pregn ancy: does fetal genotype affect outcome? Pediatric research 2007; 62(2): 120-127.Briggs G.G., Freeman R.K., Yaffe S.J. A reference guide to fetal and neonatal risk. Drugs in pregnancy and lactation. Lippincott Williams&Wilkins 2011; (9).Briggs GG, Freeman RK, Yaffe SJ. A reference guide to fetal and neon atal risk. Drugs in pregn ancy and lactation. Li ppincott Williams&Wilkins 2011; (9).Ceckova-Novatna M., Pavec P., Staud F. P-glycoprotein in the placenta: Expression, localization, regulation and function. Reproductive Toxicology 2006; 22(3): 400-410.Ceckova-Novatn a M, Pavec P, Staud F. P-glycoprotein in the placenta: Expression, localization, regulation and function. Reproductive Toxicology 2006; 22(3): 400-410.Fromm M.F. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 2004; 25(8): 423-9.Fromm MF. Importance of P-glycoprotein at blood–tissue barriers. Trends Pharmacol Sci 2004; 25(8): 423-9.EMEA. Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation. CHMP Rep; 2005; 313666.EMEA. Guideline on the exposure to medicin al products during pregn ancy: need for post-authorisation. CHMP Rep; 2005; 313666.Isoherranen N., Kenneth E. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos 2013; 41: 256-262.Isoherranen N, Kenneth E. Drug metabolism and transport during pregn ancy: how does drug disposition change during pregn ancy and what are the mechanisms that cause such changes? Drug Metab Dispos 2013; 41: 256-262.Landau R. Pharmacogenetics and obstetric anesthesia. Anesthesiol Clin 2008; 26 (1):183-95.Landau R. Pharmacogenetics and obstetric anesthesia. Anesthesiol Clin 2008; 26 (1):183-95.Mattison D.R. Clinical Pharmacology during pregnancy. ELSEVIER 2013; 471.Mattison DR. Clinical Pharmacology during pregn ancy. ELSEVIER 2013; 471.Sim S.C., Ingelman-Sundberg V. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci 2011; 32: 72-81.Sim SC, Ingelman-Sundberg V. Pharmacogenomic biomarkers: new tools in current and future drug therapy. Trends Pharmacol Sci 2011; 32: 72-81.Меркулов В.А., Бунятян Н.Д., Сакаева И.В., Лепахин В.К., Романов Б.К., Ефремова Т.А. Новые законодательные инициативы по повышению безопасности лекарственных средств в европейском союзе. Ведомости Научного центра экспертизы средств медицинского применения. 2013. № 3. С. 45-48.Merkulov VА, Bunyatyan ND, Sakaeva IV, Lepakhin VK, Romanov BK, Efremova TА. Novye zakonodatel'nye initsiativy po povysheniyu bezopasnosti lekarstvennykh sredstv v evropejskom soyuze. Vedomosti Nauchnogo tsentra ehkspertizy sredstv meditsinskogo primeneniya. 2013. № 3. S. 45-48.Кутехова Г.В., Лепахин В.К., Романов Б.К. Выявление назначения лекарственных средств с нарушениями предписаний инструкции (OFF-LABEL) в педиатрической практике. Ведомости Научного центра экспертизы средств медицинского применения. 2012. № 3. С. 23-27.Kutekhova GV, Lepakhin VK, Romanov BK. Vyyavlenie n azn acheniya lekarstvennykh sredstv s n arusheniyami predpisanij instruktsii (OFF-LABEL) v pediatricheskoj praktike. Vedomosti Nauchnogo tsentra ehkspertizy sredstv meditsinskogo primeneniya. 2012. № 3. S. 23-27.Шеффер К., Шпильман Х., Феттер К. Лекарственная терапия в период беременности и лактации. М.: Логосфера; 2010.Sheffer K, Shpilman KH, Fetter K. Drug therapy during pregn ancy and lactation. Moscow: Logosfera; 2010 (in Russian).Лепахин В.К., Романов Б.К., Торопова И.А. Анализ сообщений о нежелательных реакциях на лекарственные средства. Ведомости Научного центра экспертизы средств медицинского применения. 2012. № 1. С. 22-25.Lepakhin VK, Romanov BK, Toropova IА. Аn aliz soobshhenij o nezhelatel'nykh reaktsiyakh n a lekarstvennye sredstva. Vedomosti Nauchnogo tsentra ehkspertizy sredstv meditsinskogo primeneniya. 2012. № 1. S. 22-25.Аляутдин Р.Н., Зацепилова Т.А., Романов Б.К. Антиангинальные лекарственные средства. Российский медицинский журнал. 2007. № 4. С. 35-40.Аlyautdin RN, Zatsepilova TА, Romanov BK. Аntiangin al'nye lekarstvennye sredstva. Rossijskij meditsinskij zhurn al. 2007. № 4. S. 35-40.Reviewer guidance evaluating the risk of drug exposure in human pregnancies. U. S. Department of health and human services, food and drug administrtion, center for drug evaluation and research (CDER). Center for Biologics Evaluation and Research (CBER) 2005; 28.Reviewer guidance evaluating the risk of drug exposure in human pregn ancies. U. S. Department of health and human services, food and drug administrtion, center for drug evaluation and research (CDER). Center for Biologics Evaluation and Research (CBER) 2005; 28.Лепахин В.К., Романов Б.К., Никитина Т.Н., Снегирева И.И. Экспериза оценки отношения ожидаемой пользы к возможному риску применения лекарственных средств. Ведомости Научного центра экспертизы средств медицинского применения 2012; 2: 19-21.Lepakhin VK, Romanov BK, Nikitin a TN, Snegireva II. Expertise assess the relationshi p between the expected benefit and possible risk from the use of medicines. Scientific centre for expert evaluation of medical products bulletin. 2012; 2: 19-21.Ryon M.G., Sawhney D.S. Scientific rationale for the selection of toxicity testing methods II. Teratology, immunotoxicology, and inhalation toxicology. United States Environmental Protection Agency 1985; 253.Ryon MG, Sawhney DS. Scientific ration ale for the selection of toxicity testing methods II. Teratology, immunotoxicology, and inhalation toxicology. United States Environmental Protection Agency 1985; 253.Lo W.Y., Friedman J.M. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 2002; 100 (3): 465-73.Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregn ancy. Obstet Gynecol 2002; 100 (3): 465–73.Романов Б.К. Кальциевая регуляция активности лизосомальных ферментов миокарда. Биомедицинская химия 2005; 51 (6): 634-642.Romanov BK. Calcium regulation of activity of lysosomal enzymes of the myocardium // Biomedical chemistry 2005; 51 (6): 634-642.Шер С.А. Тератогенное воздействие лекарственных средств на организм будущего ребенка на этапе внутриутробного развития. Педиатрическая фармакология 2011; 8 (6): 57-60.Sher SA. Teratogenic effects of drugs on the body of the unborn child at the stage of fetal development. Pediatric pharmacology 2011; 8 (6): 57–60.

The authors declare that there are no conflicts of interest present.